392 related articles for article (PubMed ID: 23584575)
1. Targeting MAPK pathway in melanoma therapy.
Cheng Y; Zhang G; Li G
Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
[TBL] [Abstract][Full Text] [Related]
2. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
3. Targeting BRAF in melanoma: biological and clinical challenges.
MandalĂ M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
5. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
6. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
7. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
8. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
9. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of melanoma using kinase inhibitors.
Heppt MV; Tietze JK; Graf SA; Berking C
Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
[TBL] [Abstract][Full Text] [Related]
11. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.
Carlino MS; Long GV; Kefford RF; Rizos H
Crit Rev Oncol Hematol; 2015 Dec; 96(3):385-98. PubMed ID: 26358420
[TBL] [Abstract][Full Text] [Related]
12. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
13. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
14. Emerging BRAF inhibitors for melanoma.
Sabbatino F; Wang Y; Wang X; Ferrone S; Ferrone CR
Expert Opin Emerg Drugs; 2013 Dec; 18(4):431-43. PubMed ID: 24073999
[TBL] [Abstract][Full Text] [Related]
15. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():85-92. PubMed ID: 28169047
[TBL] [Abstract][Full Text] [Related]
16. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.
Pritchard AL; Hayward NK
Clin Cancer Res; 2013 May; 19(9):2301-9. PubMed ID: 23406774
[TBL] [Abstract][Full Text] [Related]
18. Emerging Raf inhibitors.
McCubrey JA; Steelman LS; Abrams SL; Chappell WH; Russo S; Ove R; Milella M; Tafuri A; Lunghi P; Bonati A; Stivala F; Nicoletti F; Libra M; Martelli AM; Montalto G; Cervello M
Expert Opin Emerg Drugs; 2009 Dec; 14(4):633-48. PubMed ID: 19715444
[TBL] [Abstract][Full Text] [Related]
19. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
Acosta AM; Kadkol SS
Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
[TBL] [Abstract][Full Text] [Related]
20. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]